Dragon Pharma Ipamorelin is supplied as a lyophilized powder in a 2 mL vial and contains the growth hormone-releasing peptide ipamorelin at a labeled strength of 5 mg. Product specifications, a batch-specific lab report, storage information, and available payment options are provided below.
5 mg Peptide Strength
Each vial contains a labeled strength of 5 mg of ipamorelin.
Lyophilized Powder Form
Supplied as a freeze-dried powder that requires reconstitution with bacteriostatic water before use.
2 mL Vial
Packaged in a standard 2 mL peptide vial with a rubber stopper and aluminum seal.
Published Lab Report
A published lab report from November 2023 provides measured results for the identified batch.
Product Specifications
Product name
Ipamorelin 5 mg
Active substance
Ipamorelin
Labeled strength
5 mg/vial
Container
2 mL vial
Total labeled content
5 mg per vial
Product form
Lyophilized powder
Manufacturer
Dragon Pharma
Latest Lab Result
The latest published report for batch #HDIPM923, dated November 20, 2023, measured 5.60 mg against the stated 5 mg labeled strength.
Open the Lab Reports tab to view the full report and check the batch number associated with the test.
Related Peptide Options
Other peptide options from the same product line include GHRP-2 5 mg, GHRP-6 10 mg, and CJC-1295 No DAC/Ipamorelin, which combines ipamorelin with CJC-1295 No DAC. These products differ in their peptide composition and research applications.
Published Test Result
Dragon Pharma Ipamorelin 5 mg Lab Report
A published lab report for Dragon Pharma Ipamorelin 5 mg is provided below with the test date, measured result and reported batch number. The result can be compared directly with the product's labeled strength of 5 mg.
Ipamorelin is a synthetic growth hormone-releasing peptide that acts on the ghrelin receptor to stimulate growth hormone release. This section provides a brief overview of what is known about this peptide from research literature.
1
Growth Hormone-Releasing Peptide
Ipamorelin belongs to the class of growth hormone-releasing peptides (GHRPs) that act on the ghrelin receptor to stimulate growth hormone secretion from the pituitary gland.
2
Receptor Mechanism
Ipamorelin binds to the ghrelin (growth hormone secretagogue) receptor, which is distinct from the GHRH receptor. This binding triggers a signaling cascade that leads to growth hormone release.
3
Research Applications
Preclinical research has investigated Ipamorelin for its potential effects on growth hormone release and related physiological processes. Compared with some other GHRPs, it has a relatively low effect on appetite and cortisol levels in research settings.
Peptide Reconstitution and Use
This product is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water or sterile water for injection before use. The addition of water converts the freeze-dried powder into a solution suitable for research applications.
The reconstituted peptide solution should be stored as recommended on the product label. Peptide solutions are typically refrigerated and used within a specified timeframe after reconstitution to maintain integrity.
Research References
Peer-reviewed research on Ipamorelin is available through the National Institutes of Health and other scientific databases. The following link provides general information on this peptide and its mechanism of action.
Peptide research compounds such as Ipamorelin have limited clinical safety data. The information below is derived from published preclinical research and general knowledge of the growth hormone axis and does not constitute medical advice.
Limited Clinical Data
Ipamorelin has not been extensively studied in humans. The available safety information comes primarily from preclinical research.
Growth Hormone Effects
Peptides that stimulate growth hormone release have the potential to affect glucose metabolism, insulin sensitivity and fluid balance. These effects are not well characterized for Ipamorelin.
Injection-Related Risks
Subcutaneous injection carries risks including injection-site reactions, infection and improper technique. Sterile handling and correct reconstitution procedures are essential.
Hormonal Interactions
Compounds that affect the growth hormone axis may interact with other hormonal systems, including thyroid and adrenal function. The potential significance of these interactions is not fully understood.
Central Nervous System Effects
Growth hormone-releasing peptides may have central nervous system effects in preclinical research, including effects on sleep and appetite. The clinical significance of these findings is unknown.
Contraindications
This peptide research compound should not be used by individuals with known allergies or sensitivities to peptide compounds, or by those who are pregnant, nursing or have active malignancies.
Conditions That Require Medical Review
Medical advice is particularly important for individuals with diabetes or glucose metabolism disorders, cardiovascular disease, cancer or a history of cancer, pituitary disorders, or those taking medications that affect hormone levels. This peptide should not be used during pregnancy or breastfeeding.
The product should also be stored securely to prevent accidental access or use by children or other household members, particularly after reconstitution when it contains a liquid solution.
Tested Sport
Growth hormone-releasing peptides, including Ipamorelin, are prohibited under anti-doping rules in tested sport at all times unless an applicable therapeutic-use exemption has been granted.
Quick answers about Ipamorelin 5 mg specifications, the published lab report, storage, shipping, Bitcoin payment and general product information.
What is Dragon Pharma Ipamorelin 5 mg?
Dragon Pharma Ipamorelin 5 mg is a lyophilized peptide product containing 5 mg of the growth hormone-releasing peptide ipamorelin per vial. It is supplied in a 2 mL vial for research purposes.
How much peptide is in each vial?
Each vial contains a labeled strength of 5 mg of Ipamorelin.
How is the product supplied?
The product is supplied as a lyophilized powder in a 2 mL vial. It requires reconstitution with bacteriostatic water or sterile water for injection before use.
What did the lab report show for this product?
The published lab report dated November 20, 2023 for batch #HDIPM923 measured 5.60 mg against the stated 5 mg labeled strength.
Does the lab report verify every vial?
No. Each report applies to the sample submitted for that specific test and the batch identified in the report. It does not independently verify the content or condition of every individual vial.
How should Ipamorelin be stored?
Store the lyophilized powder in its original packaging at room temperature or refrigerated, protected from excessive heat, moisture and direct light. Once reconstituted, peptide solutions typically require refrigeration and should be used within a limited timeframe. Always follow the specific storage directions printed on the product label.
Does Ipamorelin require refrigeration?
Lyophilized peptide powders are generally stable at room temperature but should be protected from heat. After reconstitution, peptide solutions typically require refrigeration. Check the product label for specific storage instructions.
How long does Ipamorelin delivery take?
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4–5 business days after dispatch, while shipments from the International Warehouse typically take 15–20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Can I buy Ipamorelin with Bitcoin?
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy Ipamorelin 5 mg with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Is Bitcoin payment anonymous?
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Is Ipamorelin permitted in tested sport?
Growth hormone-releasing peptides, including Ipamorelin, are prohibited under anti-doping rules in tested sport unless an applicable therapeutic-use exemption has been granted. Current requirements should be checked against the relevant anti-doping rules before competition.
Where can I find more information on Ipamorelin?
Additional research on this peptide is available through the National Institutes of Health and other scientific databases. A direct link to PubMed references is provided in the Science & Research section above.